Q BioMed to commercialise non-narcotic metastatic cancer pain drug
Q BioMed Inc has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain.
List view / Grid view
Q BioMed Inc has initiated production of Strontium-89 Chloride, a radiopharmaceutical indicated for the analgesic treatment of metastatic breast and prostate cancer bone pain.
MSD to invest €280 million in Ireland over the next three years bolsters the country’s status as a thriving hub for the biopharmaceutical sector...
The Asia-Pacific (APAC) asthma therapeutics market is expected to grow significantly from $4.1 billion in 2016 to around $6 billion by 2023...
Vertex Pharmaceuticals has reached an agreement with ROI to fund Orkambi for all of the approximately 500 people in Ireland with cystic fibrosis...
In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months and caused fewer side effects...
Sandoz announced that the EMA has accepted for regulatory review for biosimilars to AbbVie's Humira (adalimumab) and Janssen's Remicade (infliximab)...
Ashfield Healthcare Communications, a global healthcare communications agency, announces significant growth across the UK and Europe.
European Pharmaceutical Review caught up with Richmond Pharmacology’s CEO, Dr Jorg Taubel, to talk pioneering UK based first-in-human clinical trials…
The US Food and Drug Administration (FDA) approved Sanofi and Regeneron's Dupixent (dupilumab) injection to treat adults with moderate-to-severe eczema (atopic dermatitis).
New research projects that aim to improve the complex formulation processes used to manufacture products such as toothpastes, inhalers, films that coat solar cells and pharmaceuticals are to receive significant funding from the Engineering and Physical Sciences Research Council (EPSRC).
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…